pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. ICER points to brain swelling and potential bleeding seen in approximately 30% of patients treated with aducanumab.

FDA 98

FDA Labelling 98

pharmaphorum

DECEMBER 24, 2021

Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up to recently approved Aduhelm. The post Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA appeared first on.

FDA 109

FDA 109

pharmaphorum

OCTOBER 21, 2021

Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reverse. Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug.

Insurance 120

Insurance FDA 120

pharmaphorum

DECEMBER 17, 2021

Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug’s accelerated approval for controversial Alzheimer’s drug Aduhelm to a full one. Only a few patients have been getting treated with Aduhelm since launch, with Biogen reporting sales of $1.6

FDA 52

FDA 52

pharmaphorum

MAY 10, 2022

With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer’s disease therapy lecanemab, which is now fully filed with the FDA. The post Exit Aduhelm, enter lecanemab. Here we go again. Biogen and Eisai have another go appeared first on.

FDA 40

FDA 40

The Checkup by Singlecare

JANUARY 15, 2023

Compare donepezil alternatives | Exelon | Namenda XR | Namzaric | Razadyne ER | Aduhelm | Natural alternatives | How to switch meds. Aduhelm , the brand name of generic aducanumab, is a newer option with a novel mechanism of action in the battle against Alzheimer’s disease. Aduhelm (aducanumab). Aduhelm coupons.

Dosage 52

Dosage FDA Insurance 52

PharmD Live

DECEMBER 21, 2021

Aduhelm earns FDA approval. Aduhelm was approved by the FDA in 2021 with clinical trials outcome data indicating the potential to slow the accumulation of amyloid plaques. With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag.

FDA 52

FDA Hospitals 52